RxDoctor Payments Data

Robert Picciano, MD

Internal Medicine · Newark, NJNPI 1841210861

Payments from drug & device makers

$448in general payments, 2019–2025

Across 30 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$179
  • Novartis$62
  • Johnson & Johnson$44
  • Amgen$33
  • E.r. Squibb & Sons, L.L.C.$29
  • Pfizer$27
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$448 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$109,264
Medicare patients
208
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$64,163
EliquisApixaban61$62,548
OzempicSemaglutide45$61,563
JanuviaSitagliptin Phosphate34$49,645
Tresiba Flextouch U-100Insulin Degludec27$34,922
Tresiba Flextouch U-200Insulin Degludec23$33,676
XareltoRivaroxaban27$33,656
JanumetSitagliptin Phos/Metformin Hcl19$22,872
Icosapent Ethyl24$14,925
Breo ElliptaFluticasone/Vilanterol26$13,197
Diclofenac Sodium26$12,064
VascepaIcosapent Ethyl13$11,282
Rosuvastatin Calcium217$8,746
Atorvastatin Calcium275$4,787
Metoprolol Succinate127$3,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$62,54861 claims
Novo NordiskOzempic$179$61,56345 claims
Johnson & JohnsonXarelto$44$33,65627 claims
GSKBreo Ellipta$18$13,19726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →